NMT1 and breast carcinoma: Furthermore, treatment with a pan-NMT inhibitor, PCLX-001, decreased breast cancer cell viability in vitro and led to a dose-dependent reduction in the growth of MDA-MB-231 breast cancer xenografts, demonstrating significant NMT1 activity and supporting potential clinical utility in breast cancer (50).